Capitolis Liquid Global Markets LLC Invests $40.40 Million in Gilead Sciences, Inc. $GILD

Capitolis Liquid Global Markets LLC bought a new position in Gilead Sciences, Inc. (NASDAQ:GILD) during the third quarter, Holdings Channel reports. The fund bought 364,000 shares of the biopharmaceutical company’s stock, valued at approximately $40,404,000.

Other institutional investors and hedge funds also recently modified their holdings of the company. Ausdal Financial Partners Inc. increased its stake in Gilead Sciences by 24.4% in the 3rd quarter. Ausdal Financial Partners Inc. now owns 15,966 shares of the biopharmaceutical company’s stock worth $1,772,000 after purchasing an additional 3,135 shares in the last quarter. Bamco Inc. NY raised its holdings in Gilead Sciences by 29.7% during the 3rd quarter. Bamco Inc. NY now owns 24,000 shares of the biopharmaceutical company’s stock worth $2,664,000 after buying an additional 5,500 shares during the period. Banco Bilbao Vizcaya Argentaria S.A. lifted its stake in Gilead Sciences by 1.5% during the third quarter. Banco Bilbao Vizcaya Argentaria S.A. now owns 574,798 shares of the biopharmaceutical company’s stock valued at $63,820,000 after buying an additional 8,536 shares in the last quarter. Boothbay Fund Management LLC lifted its stake in Gilead Sciences by 12.2% during the third quarter. Boothbay Fund Management LLC now owns 2,220 shares of the biopharmaceutical company’s stock valued at $246,000 after buying an additional 241 shares in the last quarter. Finally, Ameriprise Financial Inc. boosted its holdings in shares of Gilead Sciences by 5.9% in the third quarter. Ameriprise Financial Inc. now owns 7,148,405 shares of the biopharmaceutical company’s stock worth $793,506,000 after buying an additional 400,002 shares during the period. 83.67% of the stock is owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

A number of equities research analysts have recently issued reports on the stock. The Goldman Sachs Group boosted their price target on shares of Gilead Sciences from $110.00 to $115.00 and gave the company a “neutral” rating in a report on Thursday, January 8th. Morgan Stanley raised their price objective on shares of Gilead Sciences from $150.00 to $171.00 and gave the stock an “overweight” rating in a research note on Wednesday, February 11th. Wolfe Research lifted their price objective on shares of Gilead Sciences from $155.00 to $170.00 and gave the stock an “outperform” rating in a research report on Thursday, February 12th. Wells Fargo & Company boosted their target price on shares of Gilead Sciences from $150.00 to $165.00 and gave the company an “overweight” rating in a research note on Wednesday, February 11th. Finally, UBS Group increased their target price on Gilead Sciences from $145.00 to $155.00 and gave the company a “buy” rating in a report on Monday, January 26th. Twenty-four equities research analysts have rated the stock with a Buy rating and four have given a Hold rating to the stock. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average target price of $157.62.

Gilead Sciences News Summary

Here are the key news stories impacting Gilead Sciences this week:

• Positive Sentiment: Analyst optimism — Jefferies and other firms have initiated or reiterated positive coverage, highlighting Gilead’s strong HIV franchise, expanding oncology/cell therapy pipeline and long IP runway (through ~2036), which supports both income and growth narratives. How Renewed Wall Street Optimism Around HIV, Oncology And IP Runway At Gilead Sciences (GILD) Has Changed Its Investment Story
• Positive Sentiment: Zacks raised near-term EPS estimates (Q1/Q2 and FY2027 upgrades reported), nudging earnings expectations higher — a constructive signal for investors focused on fundamentals. The Zacks Analyst Blog: Oracle, T‑Mobile, Gilead and C&F Financial
• Positive Sentiment: Unusually large call-option activity (130k+ calls) signals bullish positioning by traders, which can amplify upside if catalysts continue. (Market data)
• Positive Sentiment: Index and institutional flows — rising institutional focus amid Nasdaq‑100 dynamics can support demand for GILD shares from passive and quant funds. Gilead (NASDAQ:GILD) Institutional Focus Rises In Nasdaq 100 Index
• Neutral Sentiment: Acquisition rationale — coverage and analyst pieces discuss whether the ~$7.8B Arcellx buy strengthens Gilead’s cell‑therapy franchise amid declining cell therapy sales; the strategic case is positive but clinical/commercial risks remain. Will GILD’s Move to Acquire ACLX Boost Its Cell Therapy Franchise?
• Neutral Sentiment: Market context — broader investor flows into growth/tech vs. traditional defensives are affecting healthcare sector moves; this macro backdrop is neither uniquely positive nor negative for Gilead. Why Investors Aren’t Fleeing to Safe‑Haven Stocks
• Negative Sentiment: Deal/legal risk — a law firm (Kahn Swick & Foti) is investigating Arcellx’s proposed sale to Gilead, citing concerns over price/process; shareholder litigation or regulatory scrutiny could delay or alter the transaction terms and is a near‑term overhang. Arcellx Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Arcellx, Inc.

Insider Buying and Selling at Gilead Sciences

In other news, CFO Andrew D. Dickinson sold 3,000 shares of the stock in a transaction on Tuesday, February 17th. The shares were sold at an average price of $154.43, for a total transaction of $463,290.00. Following the transaction, the chief financial officer owned 167,779 shares in the company, valued at $25,910,110.97. This represents a 1.76% decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, CEO Daniel Patrick O’day sold 10,000 shares of the firm’s stock in a transaction on Friday, February 27th. The shares were sold at an average price of $144.79, for a total transaction of $1,447,900.00. Following the transaction, the chief executive officer owned 642,308 shares in the company, valued at $92,999,775.32. This represents a 1.53% decrease in their position. The SEC filing for this sale provides additional information. Over the last ninety days, insiders sold 309,280 shares of company stock valued at $43,935,470. 0.27% of the stock is currently owned by insiders.

Gilead Sciences Stock Down 0.2%

GILD opened at $144.99 on Friday. The company has a market capitalization of $179.99 billion, a PE ratio of 21.42, a price-to-earnings-growth ratio of 1.90 and a beta of 0.37. The company has a debt-to-equity ratio of 0.98, a current ratio of 1.55 and a quick ratio of 1.40. Gilead Sciences, Inc. has a fifty-two week low of $93.37 and a fifty-two week high of $157.29. The business has a 50-day moving average of $140.62 and a 200-day moving average of $126.87.

Gilead Sciences (NASDAQ:GILD) last announced its quarterly earnings results on Tuesday, February 10th. The biopharmaceutical company reported $1.86 EPS for the quarter, beating the consensus estimate of $1.83 by $0.03. Gilead Sciences had a return on equity of 49.46% and a net margin of 28.90%.The business had revenue of $7.93 billion during the quarter, compared to analysts’ expectations of $7.68 billion. During the same quarter in the previous year, the business posted $1.90 EPS. The firm’s quarterly revenue was up 4.7% compared to the same quarter last year. Gilead Sciences has set its FY 2026 guidance at 8.450-8.850 EPS. Equities research analysts forecast that Gilead Sciences, Inc. will post 7.95 EPS for the current fiscal year.

Gilead Sciences Increases Dividend

The firm also recently announced a quarterly dividend, which will be paid on Monday, March 30th. Shareholders of record on Friday, March 13th will be given a $0.82 dividend. This is a positive change from Gilead Sciences’s previous quarterly dividend of $0.79. This represents a $3.28 annualized dividend and a yield of 2.3%. The ex-dividend date of this dividend is Friday, March 13th. Gilead Sciences’s payout ratio is presently 46.68%.

About Gilead Sciences

Gilead Sciences, Inc, founded in 1987 and headquartered in Foster City, California, is a biopharmaceutical company focused on the discovery, development and commercialization of medicines in areas of high unmet medical need. The company initially built its reputation in antiviral therapies and has since expanded into oncology, cell therapy and inflammatory diseases. Gilead operates a global research and commercial organization, conducting clinical development and selling medicines in markets around the world.

Gilead’s product portfolio is anchored by antiviral therapies for HIV and viral hepatitis.